← Every company
Merck & Co Inc Patents
What Merck & Co Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
MRK on carbonthat →Filings on file
62
Granted
0
Still pending
62
Filed under
7 names
62 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| COMBINATIONS OF CANCER THERAPEUTICSA61P 35/02, A61K 31/404, A61P 35/00, A61K 39/001135, A61K 39/001109, A61K 31/416, A61K 31/44, A61K 31/443, A61K 31/4439, A61K 31/444, A61K 31/47, A61K 31/5025, A61K 31/506, A61K 31/517, A61K 31/53, A61K 39/395, A61K2039/505, A61K2300/00Filed as Merck Patent GmbH2026-06-15Manja Friese-Hamim | pending |
| POLYMER AND COMPOSITION COMPRISING THE SAMEC08G 77/62, C09D 183/16, H10P 14/683, H10P 14/6342, C08G 77/38, C08G 77/60, C08L 83/16, C08L2203/20Filed as Merck Patent GmbH2026-05-14Niels Schulte | pending |
| METHODS OF PURIFYING ANTI-PD-1 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF USING MIXED-MODE ANION-EXCHANGE CHROMATOGRAPHYC07K 16/2818, B01D 15/3847, C07K 1/18, C07K2317/24, C07K2317/94, B01D 15/363, B01D 15/327Filed as Merck Sharp & Dohme LLC2026-05-12Mark A. BROWER | pending |
| ORGANOMETALLIC Sn OXO CARBOXYLATE CLUSTERS WITH CARBOXYLATE LIGANDS THAT CONTAIN A LINEAR OR CYCLIC ESTER FUNCTIONALITYC07F 7/2224, G03F 7/0042, G03F 7/162Filed as Merck Patent GmbH2026-05-08Niels Lichtenberger | pending |
| ELECTRONIC DEVICEH10K 85/636, C07D 311/96, H10K 85/633, H10K 50/181, H10K 50/17, H10K 85/6574, H10K 85/6576, H10K 85/615, H10K 50/156, H10K 50/15, H10K 85/626, H10K 85/6572, C07D 335/04, C07D 405/04, C07D 405/10, C07D 405/14, C07D 407/12, C07D 409/12, C09K 11/06, C09K2211/1018, Y02E 10/549Filed as Merck Patent GmbH2026-05-05Frank VOGES | pending |
| ELECTRONIC DEVICE MANUFACTURING AQUEOUS SOLUTION, METHOD FOR PRODUCING RESIST PATTERN, AND METHOD FOR MANUFACTURING DEVICEC11D 1/22, G03F 7/405, C11D2111/22, H10P 76/2041, H10P 70/23, H10P 50/695, H10P 50/242, C11D 1/14, C11D 3/3418, C11D 3/349, C11D 3/43, G03F 7/0392, G03F 7/2004, G03F 7/40, G03F 7/426Filed as Merck Patent GmbH2026-04-24Hiroshi Yanagita | pending |
| MATERIALS FOR ELECTRONIC DEVICESH10K 85/6574, C07D 307/91, H10K 85/636, H10K 85/633, H10K 50/181, H10K 85/615, H10K 50/15, H10K 85/626, C07D 493/04, C09K 11/06, C09K2211/1011Filed as Merck Patent GmbH2026-04-17Rouven Linge | pending |
| APTAMERS SPECIFIC FOR TLR-4 AND USES THEREOFA61P 29/00, C12N 15/115, A61P 27/02, A61P 25/36, A61P 37/02, A61P 9/10, A61P 25/30, A61P 43/00, A61P 9/00, A61P 19/02, A61P 31/04, A61P 25/00, A61K 31/7088, A61K 45/06, A61K 48/005, A61K 49/0013, A61K 49/04, A61K 51/00, C12N 15/1138, C12N2310/16, C12N2310/53, G01N 33/566, G01N 33/68, G01N 33/6893, G01N2333/705, G01N2333/70596, G01N2800/164, G01N2800/2871, A61K2300/00Filed as Merck Patent GmbH2026-04-14Ignacio Lizasoain Hernandez | pending |
| Compound and Composition Comprising the SameC07F 7/0838, C08G 77/42, H10W 20/097, B05D 3/046, B05D2518/12, C08G 77/045, C08G 77/20, C08G 77/54, C08G2150/00, C08L 83/08, C08L 83/14, C08L2203/16, C08L2203/206, C08L2205/025Filed as Merck Patent GmbH2026-04-13Manchao Xiao | pending |
| RIPK1 INHIBITORS AND METHODS OF USEC07D 487/04, A61P 25/28, A61P 25/00, A61K 31/4196, A61K 31/429, A61K 31/437, A61K 31/4439, A61K 31/497, A61K 31/5383, C07D 471/04, C07D 498/04, C07D 513/04Filed as Merck Sharp & Dohme LLC2026-04-02Joanna L. Chen | pending |
| TRICYCLIC AGONISTS OF TREM2Filed as MERCK SHARP & DOHME LLC2026-03-20YAROSLAV BOYKO | pending |
| SLC15A4-TASL PATHWAY INHIBITORSFiled as MERCK SHARP & DOHME LLC2026-03-18SARAH N. DISHMAN | pending |
| SOLID DOSAGE FORMULATIONS OF AN OREXIN RECEPTOR ANTAGONISTA61K 31/551, A61P 1/14, A61P 25/20, A61P 25/28, A61P 5/02, A61P 9/00, A61P 11/06, A61P 25/22, A61P 3/04, A61P 3/10, A61P 9/12, A61P 25/18, A61P 25/24, A61P 25/00, A61P 25/08, A61P 25/16, A61P 1/04, A61P 1/08, A61P 25/06, A61P 35/00, A61K 9/2013, A61K 9/2018, A61K 9/2027, A61K 9/2054, A61K 47/00, A61K 47/32, A61K 47/38Filed as Merck Sharp & Dohme LLC2026-03-18Paul A. Harmon | pending |
| REACTIVE MESOGENSC07C 69/533, C09K 19/18, C07C2602/10, C07C2603/24, C07C 255/54, C07C 323/09, C07D 209/12, C07D 333/76, C07D 495/04, C08J 5/18, C09K2019/0448, C09K2019/2092Filed as MERCK PATENT GMBH2026-03-12Kevin Adlem | pending |
| PYRIDONE AND PYRAZINONE AGONISTS OF TREM2Filed as MERCK SHARP & DOHME LLC2026-03-12JOANNA L. CHEN | pending |
| METAL EFFECT PIGMENT-FREE RADAR-COMPATIBLE COATING ON A SUBSTRATEC09D 7/70, C09D 7/62, C01P2006/62, C08K 3/346, C08K 9/02, C09C 1/0015, C09C 1/0042, C09C2200/1004, C09C2200/102, C09D 1/00, C09D 5/29, C09D 5/32Filed as Merck Patent GmbH2026-03-10Udo GUMSHEIMER | pending |
| MULTICOMPONENT CRYSTALLINE SOLID FORMS OF SODIUM CAPRATEFiled as MERCK SHARP & DOHME LLC2026-03-06MUSTAFA BOOKWALA | pending |
| LONG-ACTING INJECTABLE FORMULATIONS OF HIV REVERSE TRANSCRIPTASE INHIBITORSFiled as MERCK SHARP & DOHME LLC2026-03-06TAMARA CABALU | pending |
| LIQUID-CRYSTAL MEDIUMC09K 19/3098, C09K 19/3491, G02F 1/136277Filed as MERCK PATENT GMBH2026-03-04Izumi SAITO | pending |
| COMBINATIONS FOR THE TREATMENT OF PROSTATE CANCERFiled as MERCK SHARP & DOHME LLC2026-03-03KENTARO IMAI | pending |
| MATERIALS FOR ORGANIC ELECTRONIC DEVICESC07D 213/38, H10K 85/624, H10K 85/654, H10K 85/636, H10K 85/633, H10K 50/181, H10K2101/90, H10K2101/10, H10K 85/631, H10K 85/6574, H10K 50/11, H10K 85/6576, H10K 85/615, H10K 50/15, H10K 85/6572, C07D 209/88, C07D 239/26, C07D 251/24, C07D 307/91, C07D 333/76, C07D 403/04, C07D 403/10, C07D 405/12, C07D 409/12, C07D 409/14, C09K 11/06, Y02E 10/549Filed as Merck Patent GmbH2026-03-02Christian WIRGES | pending |
| 3D BIOPRINTED MODEL FOR QUANTIFYING NEURITE OUTGROWTHFiled as MERCK SHARP & DOHME LLC2026-02-27CHLOE ANN WHITEHOUSE | pending |
| 3D Bioprinted Model for Quantifying Neurite OutgrowthB33Y 80/00, C12N 5/0619, B33Y 10/00, C12M 25/14, C12M 35/08, C12M 41/46, C12N 5/0062, C12N 5/0618, C12N 5/0622, C12N 5/0623, C12N 5/0697, C12N2501/115, C12N2501/13, C12N2502/081, C12N2502/086, C12N2503/02, C12N2506/02, C12N2506/45, C12N2513/00, C12N2533/32, C12N2533/52, C12N2533/74, C12N2533/80, C12N2533/90, C12N2537/10Filed as Merck Sharp & Dohme LLC2026-02-27Chloe Ann Whitehouse | pending |
| METHOD FOR MANUFACTURING CURED FILM AND USE OF THE SAMEG03F 7/091, G03F 7/11, H10P 76/2043, C08G 61/10, C08G2261/124, C08G2261/1424, C08G2261/18, C08G2261/228, C08G2261/312, C08G2261/3142, C09D 165/00, G03F 7/025, G03F 7/027, G03F 7/0388, G03F 7/094, G03F 7/20Filed as Merck Patent GmbH2026-02-25Takashi SEKITO | pending |
| SUSTAINED-RELEASE FORMULATIONS FOR POORLY PERMEABLE CYCLIC PEPTIDESFiled as MERCK SHARP & DOHME LLC2026-02-18Oscar EKPENYONG | pending |
| POLYMERIZABLE LIQUID CRYSTAL FORMULATIONSC09K 19/52, C09K2323/02, C09D 11/36, C09D 11/38, C09K 19/12, C09K 19/18, C09K 19/2007, C09K 19/2014, C09K 19/3003, C09K 19/3068, C09K 19/322, C09K 19/3402, C09K 19/3405, C09K 19/3444, C09K 19/3477, C09K 19/3491, C09K 19/3852, C09K 19/46, C09K2019/0444, C09K2019/0448, C09K2019/122, C09K2019/181, C09K2019/183, C09K2019/188, C09K2019/2035, C09K2019/3004, C09K2019/3016, C09K2019/3075, C09K2019/323, C09K2019/3408, C09K2019/525, C09K2219/03, G02B 5/3016Filed as MERCK PATENT GmbH2026-02-17Oleksandra Shargaieva | pending |
| ANTI-HUMAN PD-1 ANTIBODY CRYSTALS AND METHODS OF USE THEREOFA61K 47/6849, A61P 35/00, C07K 16/2818, C07K 16/11, A61K 31/522, A61K 45/06, A61K 47/10, A61K2039/505, A61K2039/545, C07B2200/13, C07K 16/244, C07K 16/2803, C07K 16/2863, C07K 16/2878, C07K 16/36, C07K2299/00, C07K2317/21, C07K2317/24, C07K2317/76, C30B 29/58Filed as Merck Sharp & Dohme LLC2026-02-13Paul Reichert | pending |
| Liquid Crystal MediumC09K 19/30, C09K 19/3098, C09K 19/3491, C07C 39/23, C07D 211/46, C09K 19/3048, C09K 19/3066, C09K 19/3402, C09K 19/44, C09K2019/0466, C09K2019/123, C09K2019/124, C09K2019/3004, C09K2019/3009, C09K2019/301, C09K2019/3016, C09K2019/3019, C09K2019/3021, C09K2019/3027, C09K2019/3037, C09K2019/3078, C09K2019/3422, G02F 1/1333, G02F 1/137Filed as MERCK PATENT GMBH2026-02-12Jing Wang | pending |
| LIQUID CRYSTALLINE MEDIUM AND COMPOUNDSC09K 19/3405, C09K 19/42, C07D 471/04, C09K 19/12, C09K 19/3003, C09K 19/3068, C09K 19/3098, C09K 19/3491, C09K 19/44, C09K2019/0466, C09K2019/122, C09K2019/123, C09K2019/124, C09K2019/3004, C09K2019/3006, C09K2019/3009, C09K2019/301, C09K2019/3016, C09K2019/3025, C09K2019/3027, C09K2019/3408, C09K2019/3422, G02F 1/1333Filed as MERCK PATENT GMBH2026-02-12Sven Christian LAUT | pending |
| COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIESA61K 39/39541, C07K 16/2818, A61P 35/04, A61P 35/00, A61K 33/243, A61K 9/0019, A61K 9/08, A61K 9/19, A61K 31/282, A61K 31/337, A61K 31/519, A61K 31/573, A61K 31/714, A61K 38/47, A61K 39/3955, A61K 45/06, A61K 47/183, A61K 47/26, A61K 47/36, A61K2039/505, A61K2039/54, A61K2039/545, A61K2300/00, C07K2317/24, C07K2317/94, C12N 9/2402, C12N 9/2474, C12Y 302/01035Filed as MERCK SHARP & DOHME LLC2026-02-09Omobolaji AKALA | pending |
| COMBINATIONS AND METHODS FOR WEIGHT MANAGEMENTFiled as MERCK SHARP & DOHME LLC2026-02-09ERIN SHIER COYNE | pending |
| FORMULATIONS FOR SELECTIVE DEPOSITIONFiled as Merck Patent GmbH2026-02-05Christopher R. Clough | pending |
| METHOD FOR PURIFICATION OF PLASMID DNAFiled as Merck Patent GmbH2026-02-02Alisa STROBEL | pending |
| LONG-ACTING INJECTABLE FORMULATIONS OF HIV REVERSE TRANSCRIPTASE INHIBITORSFiled as Merck Sharp & Dohme LLC2026-01-30Seth P. Forster | pending |
| FORMULATIONS OF ANTI-RSV ANTIBODIES AND METHODS OF USE THEREOFC07K 16/11, A61K 39/39591, A61K 47/547, A61P 31/14, A61K 9/0019, A61K 9/19, A61K 47/12, A61K 47/183, A61K 47/22, A61K 47/26, A61K2039/54, A61K2039/545, C07K 16/24, C07K2317/565, C07K2317/94Filed as Merck Sharp & Dohme LLC2026-01-28Venus Hashemi | pending |
| METHODS FOR PRODUCTION OF CAPSULAR POLYSACCHARIDE PROTEIN CONJUGATES FROM STREPTOCOCCUS PNEUMONIAE SEROTYPE 19FA61K 47/646, C07K 14/34, G01N 33/56944, A61K 47/6415, A61K 39/092, A61K 47/36, A61K2039/6037, G01N2333/315, G01N2333/345Filed as Merck Sharp & Dohme LLC2026-01-27Michael Albert Winters | pending |
| HYDROPHILIC MEMBRANESB01D 61/145, B01D 67/0013, B01D2323/60, B01D 61/147, B01D 67/0009, B01D 67/0011, B01D 67/009, B01D 69/02, B01D 69/141, B01D 71/58, B01D 71/62, B01D 71/68, B01D2313/44, B01D2323/30, B01D2323/34, B01D2325/022, B01D2325/04, B01D2325/24, B01D2325/36Filed as Merck Millipore Ltd.2026-01-26Jijun Ge | pending |
| LIQUID-CRYSTALLINE MEDIUMC09K 19/3098, C09K 19/3491, G02F 1/137, C09K 19/12, C09K 19/3003, C09K 19/3028, C09K 19/3048, C09K 19/3068, C09K 19/3402, C09K 19/3405, C09K 19/44, C09K 19/54, C09K2019/0448, C09K2019/0466, C09K2019/122, C09K2019/123, C09K2019/125, C09K2019/3004, C09K2019/3009, C09K2019/301, C09K2019/3012, C09K2019/3016, C09K2019/3019, C09K2019/3025, C09K2019/3042, C09K2019/3077, C09K2019/3083, C09K2019/3408, C09K2019/3422, G02B 27/017, G06F 3/012Filed as MERCK PATENT GMBH2026-01-23Sven Christian Laut | pending |
| SMALL MOLECULE INHIBITORS OF KRAS PROTEINSFiled as MERCK SHARP & DOHME LLC2026-01-23MELANIE A.S. BLACKBURN | pending |
| LIQUID-CRYSTALLINE MEDIUMG02F 1/13706, C09K 19/3098, C09K 19/3491, C09K 19/12, C09K 19/20, C09K 19/3003, C09K 19/3028, C09K 19/3048, C09K 19/3066, C09K 19/3402, C09K 19/3405, C09K 19/44, C09K 19/54, C09K2019/0448, C09K2019/0466, C09K2019/122, C09K2019/123, C09K2019/3004, C09K2019/3009, C09K2019/301, C09K2019/3016, C09K2019/3027, C09K2019/3036, C09K2019/3037, C09K2019/3408, C09K2019/3422, C09K2019/3425Filed as MERCK PATENT GmbH2026-01-23Sven Christian Laut | pending |
| COMBINATIONS FOR THE TREATMENT OF CANCERFiled as MERCK SHARP & DOHME LLC2026-01-20JAIME ALBERTO MEJIA | pending |
| BISPECIFIC ANTIBODY CONSTRUCTS THAT BIND ALPP/ALPPL2 AND CD3Filed as MERCK SHARP & DOHME LLC2026-01-14DAVID BAUCHE | pending |
| ALPP AND/OR ALPPL2 BINDERS AND THEIR USEFiled as MERCK SHARP & DOHME LLC2026-01-14DAVID BAUCHE | pending |
| BISPECIFIC ANTIBODY CONSTRUCTS THAT BIND ALPP/ALPPL2 AND CD3Filed as MERCK SHARP & DOHME LLC2026-01-14DAVID BAUCHE | pending |
| SYSTEM AND METHOD FOR ESTIMATING GREENHOUSE GAS EMISSIONS IN AN ENVIRONMENT HOUSING AN ANIMAL POPULATIONA61B 5/0205, G06F 1/00, G06Q 30/018, G16H 20/30, G16H 40/67, G16H 50/30, G16H 20/60, G16H 20/70, A61B 5/0022, A61B 5/097, A61B2503/40, F02D 41/1438, F02D 41/1444, G06Q 10/0639, G06Q 50/02Filed as MERCK SHARP & DOHME ANIMAL HEALTH, S.L.2026-01-13Eran GENZEL | pending |
| SELF-LUBRICATING CO-PROCESSED EXCIPIENT SYSTEM FOR SOLID DOSAGE FORMSFiled as Merck Patent GmbH2026-01-05Lena Mueller | pending |
| MATERIALS FOR ELECTRONIC DEVICESFiled as Merck Patent GmbH2026-01-05Elvira Montenegro | pending |
| METHODS AND COMPOSITIONS FOR PURIFYING ADENO ASSOCIATED VIRUS PARTICLESFiled as MERCK PATENT GMBH2026-01-05Alice ANTONELLO | pending |
| AROMATIC HETEROCYCLIC DERIVATIVE, AND ORGANIC ELECTROLUMINESCENT ELEMENT, ILLUMINATION DEVICE, AND DISPLAY DEVICE USING AROMATIC HETEROCYCLIC DERIVATIVEC07D 209/82, C07D 405/14, H10K 85/654, H10K 85/6574, H10K 50/11, H10K 85/6576, H10K 85/6572, C07D 409/14, C09K 11/06, C09K2211/1029, C09K2211/1044, C09K2211/1059, C09K2211/1088, C09K2211/1092Filed as Merck Patent GmbH2026-01-05Motoaki SUGINO | pending |
| PCSK9 ANTAGONIST COMPOUNDSC07D 498/22, C07K 7/56, A61K 47/542, A61P 3/06, A61K 38/00, C07K 7/64, C12N 9/6424, C12Y 304/21Filed as MERCK SHARP & DOHME LLC2025-12-30Hubert JOSIEN | pending |
| COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCERA61K 39/39558, C07K 16/2818, A61P 43/00, A61P 35/02, A61P 13/12, A61P 35/00, A61K 31/4439, A61K 45/06, A61K2039/505, A61K2039/545, A61K2300/00, C07K 16/30, C07K 16/3015, C07K 16/3023, C07K 16/303, C07K 16/3038, C07K 16/3053, C07K 16/3061, C07K 16/3069, C07K2317/24, C07K2317/76Filed as MERCK SHARP & DOHME LLC2025-12-29Jean-Francois Andre Martini | pending |
| NOVEL TREATMENT REGIMEN FOR THE TREATMENT OF AUTOIMMUNE DISORDERSA61P 37/00, A61K 31/7076, A61K 39/25, A61P 31/22, A61P 37/04, Y02A 50/30, A61K 39/215, A61K2039/5252, A61K2039/53, A61K2039/545, A61K2039/55, C12N2710/16734, C12N2770/20033Filed as Merck Patent GmbH2025-12-23Ursula Boschert | pending |
| IMIDAZO[1,2-A]PYRAZIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF A HELMINTH INFECTIONC07F 9/6561, A61P 33/12, A61K 31/4985, A61K 31/675, A61K 45/06, C07D 487/04Filed as Merck Patent GmbH2025-12-19Shashank Kulkarni | pending |
| AMORPHOUS BIOLOGIC SUSPENSIONS AND METHODS OF USE THEREOFFiled as MERCK SHARP & DOHME LLC2025-12-19PAUL REICHERT | pending |
| SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANTFiled as MERCK SHARP & DOHME LLC2025-12-19THOMAS BARA | pending |
| SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANTFiled as MERCK SHARP & DOHME LLC2025-12-18JUAN DEL POZO | pending |
| DIFFRACTIVE OPTICAL ELEMENTG02B 5/1814, G02B 5/1833, G02F 1/292, G02B 1/16, G02B 1/18, G02F 1/133726, G02F 1/133638, G02F 1/133543, H10K 59/8793, C09K 19/18, C09K 19/2007, C09K2019/0448, G02B 5/08, G02B 5/1828, G02B 5/1842, G02B 5/1866, G02B 5/3016, G02B 5/3083, G02B 27/0172, G02B 27/0944, G02B 27/42, G02B 27/4211, G02B 27/4272, G02F 1/0045, G02F 1/133504Filed as MERCK PATENT GMBH2025-12-18Stephen Mulcahy | pending |
| MULTI-TWIST WAVEPLATEC09K 19/3861, G02B 5/1814, G02B 5/3016, G02F 1/133638, C09K 19/2007, C09K 19/3059, C09K 19/3852, C09K2019/0444, C09K2019/0448, C09K2019/2035, C09K2019/2078, C09K2219/03, G02B 5/1833, G02B 5/1842, G02B 5/1857, G02B 5/3083, G02B 27/52, G02F 1/1396, G02F 1/292, G02F2201/305Filed as MERCK PATENT GMBH2025-12-18Stephen Mulcahy | pending |
| HALF-WAVE PLATEG02B 1/04, G02B 5/3083Filed as MERCK PATENT GMBH2025-12-18Stephen Mulcahy | pending |
| SCORING METHODS FOR ANTI-PD THERAPY ELIGIBILITY AND COMPOSITIONS FOR PERFORMING SAMEG01N 33/5759, G01N2333/70532, G01N2800/52Filed as MERCK SHARP & DOHME LLC2025-12-16Karina KULANGARA | pending |
| MOVABLE DOUBLE PADDLEFiled as MERCK SHARP & DOHME LLC2025-12-16YASUHIRO TSUME | pending |
| INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUSFiled as MERCK SHARP & DOHME LLC2025-12-16Douglas C. BESHORE | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on MRK
Company overviewEverything on MRK in one place, with the price.SEC filingsWhat MRK's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat MRK's own officers and directors buy and sell.Who owns itEvery manager reporting a position in MRK.Funds holding itWhich funds and ETFs hold MRK, and how big a bet.LobbyingWhat MRK spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on MRK's account, and who they worked for.Federal contractsWhat federal agencies pay MRK.